Alterity Therapeutics Lim... (ATHE)
NASDAQ: ATHE
· Real-Time Price · USD
4.39
-0.03 (-0.57%)
At close: Jun 17, 2025, 3:00 PM
-0.57% (1D)
| Bid | 4.33 |
| Market Cap | 64.94M |
| Revenue (ttm) | 4.78M |
| Net Income (ttm) | -26.1M |
| EPS (ttm) | -1.95 |
| PE Ratio (ttm) | -2.25 |
| Forward PE | -5.16 |
| Analyst | Strong Buy |
| Ask | 4.47 |
| Volume | 2,825 |
| Avg. Volume (20D) | 39,792 |
| Open | 4.35 |
| Previous Close | 4.42 |
| Day's Range | 4.35 - 4.50 |
| 52-Week Range | 1.00 - 5.87 |
| Beta | 0.72 |
About ATHE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ATHE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ATHE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+26.45%
Alterity Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
+57.04%
Alterity Therapeutics shares are trading higher after the company reported topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy, showing clinically meaningful benefits at both doses studied.
